The Race for Avandia's Share: May the Safest Product Win
This article was originally published in RPM Report
Executive Summary
The safety problems with GlaxoSmithKline's Avandia have left a large chunk of the diabetes market open to competing products, and the outcome of an FDA advisory committee meeting could leave even more up for grabs. Who will be the big winner in the race for market share?
You may also be interested in...
Don't Cry Too Hard for Avandia
GSK suffered a major commercial loss after news of Avandia's cardiovascular safety exploded onto the market in 2007. But there is a sliver of a silver lining for GSK: FDA's post-Avandia safety rules may make it tougher for new competing products to reach the market.
Don't Cry Too Hard for Avandia
GSK suffered a major commercial loss after news of Avandia's cardiovascular safety exploded onto the market in 2007. But there is a sliver of a silver lining for GSK: FDA's post-Avandia safety rules may make it tougher for new competing products to reach the market.
The Avandia Penumbra: Remapping Diabetes Drug Development
The implosion of Avandia has raised several critical issues for diabetes drug developers, including whether companies can still rely on glycemic control as the primary endpoint for approval and the extent to which late-stage comparative trials conducted versus Avandia are still useful. The decisions FDA makes in the wake of Avandia will also be important milestones affecting other therapeutic categories, as they will reflect how the agency is assessing and monitoring drug safety generally.